ReviewJournal of clinical and experimental dentistry2026
Curcumin in oral potentially malignant disorders and oral squamous cell carcinoma: Clinical and biological evidence from a systematic review.
Review in Journal of clinical and experimental dentistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral squamous cell carcinoma is associated with poor survival and frequently develops from oral potentially malignant disorders, particularly oral leukoplakia and oral lichen planus. Conventional management is mainly based on the removal of clinically altered areas; however, the risk of progression may persist. In this context, curcumin, a natural compound derived from turmeric with antioxidant, anti-inflammatory, and antineoplastic properties, has been investigated as a potential therapeutic alternative. Materials and Methods: A qualitative systematic review was conducted following the Cochrane Handbook and PRISMA guidelines. Literature was searched in MEDLINE (PubMed), Web of Science, Scopus, and SciELO (September-December 2025), including human studies from the last 15 years in English, Spanish, or Portuguese. Studies on adult patients with oral leukoplakia, oral lichen planus, or oral squamous cell carcinoma treated with curcumin or Curcuma longa derivatives (oral or topical) were included. Outcomes assessed included clinical efficacy (lesion size and symptoms), anti-inflammatory effects, and molecular biomarkers. Results: A total of 1,527 articles were identified, of which 18 met the inclusion criteria, comprising 1,189 participants. Most studies were clinical trials. In oral leukoplakia, all studies reported clinical improvement, mainly reflected by lesion size reduction, although without consistent histopathological changes. In oral lichen planus, eight of ten studies showed reductions in pain and lesion size, with decreases in VAS scores and statistically significant differences (p<0.05). Relevant reductions in lesion size were also observed (p<0.05). In oral squamous cell carcinoma, a significant decrease in inflammatory cytokines (IL-1β, IL-8, TNF-α) was reported. Comparable efficacy to corticosteroids was observed in most comparative studies. Conclusions: The use of curcumin appears to provide favorable clinical effects and relevant anti-inflammatory benefits in oral leukoplakia, oral lichen planus, and oral squamous cell carcinoma, mainly reflected by reductions in pain and lesion size. However, further well-designed clinical trials are required to confirm its efficacy and to better define its role in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.